Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

FDA Warns of Liver Injury From Muscle-Building Supplement

By Pharmaceutical Processing | April 14, 2015

WASHINGTON (AP) — The Food and Drug Administration is warning consumers to avoid dietary supplements sold by a Las Vegas company because they may contain anabolic steroids that can cause liver damage.

The agency said it is investigating Tri-Methyl Xtreme supplements after three reported injuries from users in California, New Jersey and Utah.

Extreme Products Group, of Las Vegas, distributes the capsules as a muscle-building supplement, and claims that they contain anabolic steroids. The products are sold online and by some retailers and gyms, the FDA said in a statement Monday. Calls placed to Extreme Products Group were not immediately returned.

The FDA says consumers who have taken the supplements should watch out for potential signs of adverse effects, including unexplained fatigue, abdominal or back pain or discolored urine.

“Anabolic steroids may have a range of serious adverse effects on many organ systems, and the damage may be irreversible,” said Dr. Charles Lee, a senior scientist with the FDA, in a statement.

Synthetic steroids can cause a number of dangerous side effects, including liver injury, and increase risks of heart attack and stroke.

The FDA has struggled for years to crack down on dietary supplements that are spiked with prescription drugs. Under longstanding regulations, supplements do not undergo FDA review for safety and effectiveness before they are marketed. Instead, manufacturers are responsible for making sure their products are safe.

Supplements cannot contain prescription drug ingredients. But the FDA issues frequent warnings about drug-containing supplements marketed for weight loss, body building, sexual enhancement and other purposes.

Last year, findings published in the Journal of the American Medical Association showed that drug-containing supplements can stay on the market years after they are recalled. Of 27 supplements tested by Cambridge Health Alliance researchers, 17 still contained the same drug that prompted their recall.

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2026 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE